Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03438487 · ClinicalTrials.gov registry record
Flucelvax (TIVc or QIVc) Pregnancy Registry
A clinical trial, sponsored by Seqirus.
- Completed
- Registry status
- 692
- Enrollment target
NCT03438487 is a clinical trial that has completed, run by Seqirus. The registered enrollment target is 692 participants.
The verdict
NCT03438487 has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- 692 participants
- Enrollment target
Study Summary
The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy.
Interventions
- BIOLOGICAL Flucelvax Trivalent Influenza Vaccine
- BIOLOGICAL Flucelvax Quadrivalent Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 692 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2020-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03438487
The ClinicalTrials.gov registry entry for NCT03438487 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 692 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Flucelvax Trivalent Influenza Vaccine is the first listed.
NCT03438487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03438487 about?
NCT03438487 is a clinical study titled "Flucelvax (TIVc or QIVc) Pregnancy Registry". The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy.
What is the current status of trial NCT03438487?
This trial is currently completed. The enrollment target is 692 participants. The study started on 2017-09-01. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03438487?
The interventions under investigation include: Flucelvax Trivalent Influenza Vaccine (BIOLOGICAL), Flucelvax Quadrivalent Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03438487?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.